Stockscreener 앱 받기
3.59
4.36%
0.15
시간 외 거래:
3.65
0.06
+1.67%
Neuphoria Therapeutics Inc 주식(NEUP)의 최신 뉴스
NEUPNeuphoria Therapeutics Inc Latest SEC Filings - Finviz
MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership - MSN
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership - Asianet Newsable
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer's Drug Trial Under Neuphoria Partnership - Menafn
Scancell Confirms Advanced Talks for Potential Acquisition of Nasdaq-listed Neuphoria Therapeutics - Moomoo
Neuphoria confirms merger talks with Scancell Holdings - Investing.com UK
Neuphoria confirms merger talks with Scancell Holdings By Investing.com - Investing.com Nigeria
Neuphoria Therapeutics (NEUP) Confirms Acquisition Talks with Sc - GuruFocus
Neuphoria Therapeutics Inc's stock price recorded a significant increase of 6% in after-hours trading, closing at $4.85. - Bitget
Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell - TradingView
Neuphoria TherapeuticsConfirms Discussions - Moomoo
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc - GlobeNewswire
Neuphoria Therapeutics Inc. Actuals & Estimates (NASDAQ:NEUP) - TradingView
Scancell in talks for reverse merger with Neuphoria Therapeutics - Investing.com
Scancell confirms advanced talks over reverse merger with Neuphoria - Proactive financial news
Scancell confirms advanced talks on takeover of Neuphoria; eyes Nasdaq - marketscreener.com
Scancell in talks for reverse merger with Neuphoria Therapeutics By Investing.com - Investing.com Canada
NEUP Forecast — Price Target — Prediction for 2027 - TradingView
Scancell confirms advanced reverse merger talks with US-listed Neuphoria - Share Talk
Scancell Confirms Advanced Talks over Reverse Merger with Neuphoria - marketscreener.com
Neuphoria Therapeutics Inc (NEUP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuphoria Therapeutics Inc (NEUP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuphoria Therapeutics Inc (NEUP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuphoria Therapeutics Inc (NEUP) Institutional Confidence - TradingKey
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuphoria Therapeutics Inc (NEUP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuphoria Therapeutics Inc (NEUP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuphoria Therapeutics (NEUP) Holds Near Support With Minimal Price MovementFundamental Weighted - Město Břeclav
NEUP Q1 2026 Earnings: Surprise EPS Beat Highlights Cost Discipline Despite Pre-Revenue StatusOne-Time Loss Impact - lwvtexas.org
Neuphoria Therapeutics Inc. Financial Disclosures & SEC Filings - TradingView
Neuphoria Therapeutics (NEUP) Registration filing Summary - Quartr
NEUP Q1 2026 Earnings: EPS Surprises with 90.9% Beat Amid No RevenueBook Value Growth - The Legal Advocate
NEUP Q1 2026 Earnings: Significant EPS Beat Amidst Revenue AbsenceCapex Guidance - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower as Consolidation Continues Near SupportFlat Correction - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower Amid Consolidation Near SupportBollinger Band - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowed Loss Surprises as Pre-Revenue Stage ContinuesPreliminary Results - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowing Losses Beat Estimates Sharp, Yet Shares SlipRevenue Guidance Update - The Legal Advocate
Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial - The Globe and Mail
Neuphoria Therapeutics (NEUP) Holds Steady Near Support – Can the Range Hold?Fibonacci Arc - newsline.com
Neuphoria Therapeutics (NEUP) Slips Amid Sector Headwinds – Key Support Levels in FocusSize Factor - The Legal Advocate
Neuphoria Therapeutics (NEUP) Soars 7%: Key Levels to Watch After Bullish BreakoutKey Reversal Day - Newser
NEUP Q1 2026 Earnings: Wider-Than-Expected Loss Narrows Sharply as Clinical Pipeline Progress Drives Investor OptimismEPS Surprise History - The Legal Advocate
NEUP Q1 2026 Earnings: Steeper-Than-Expected Loss Narrowing Fuels Post-Report RallyEarnings Surprise Score - Newser
What Neuphoria Therapeutics (NEUP)'s +1.62% Jump Means for Investors 2026-05-21Wave Extension - The Legal Advocate
NEUP Stock Moves Higher as Traders Focus on Neuphoria’s Cash Runway - Bez Kabli
Neuphoria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
1.17%
2.48%
자본화:
|
볼륨(24시간):